FDA’s Arthritis Advisory Committee reviews data supporting Amgen’s BLA for ABP 501 (biosimilar adalimumab).
Home / Search Results
Stay informed about important legal and industry news with our blogs and weekly BioBlast® updates.
By Bioblast Editor | Jun 13, 2016
FDA’s Arthritis Advisory Committee reviews data supporting Amgen’s BLA for ABP 501 (biosimilar adalimumab).
By Bioblast Editor | May 30, 2016
Biogen/Samsung Biopeis receive EMA approval for Flixabi®, biosimilar Infliximab.
By Bioblast Editor | May 16, 2016
Sorrento releases results of Phase II and III clinical trials of biosimilar omalizumab, announcing the candidate STI-004 demonstrated clinical efficacy and safety.
By Bioblast Editor | Apr 05, 2016
Pfizer/Celltrion received FDA approval for Inflectra®, biosimilar infliximab.
By Bioblast Editor | Apr 01, 2016
EU’s CHMP gives green light for Flixabi®, Samsung Bioepis’ biosimilar infliximab.
By Bioblast Editor | Mar 24, 2016
Samsung Bioepis files suit in the UK to remove Abbvie patents regarding adalimumab.
By Bioblast Editor | Feb 11, 2016
EMA accepts Sandoz’s filing for Zioxtenzo, biosimilar pegfilgrastim.
By Bioblast Editor | Jan 17, 2016
EMA approves Benepali®, biosimilar etanercept (SB4) for the treatment of rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis and plaque psoriasis. CHMP positive opinion was announced on 20 Nov 2015. Samsung says it developed, tested and had its Benepali® app...
By Bioblast Editor | Jan 11, 2016
MabTech announces successful Chinese Ph III clinical trials for Sorrento’s “biosimilar/biobetter” cetuximab STI-001, and infliximab STI-002.
By Bioblast Editor | Jan 11, 2016
MabTech announces successful Chinese Ph III clinical trials for Sorrento’s “biosimilar/biobetter” cetuximab STI-001, and infliximab STI-002.
SUBSCRIBE TO PEARCE IP